Recent Updates
Recently added Catalysts

Advanced Solid Tumors With FGFR1 Amplification: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$1.9Buniverse median $1.20B
Allocated capital$967M$1.9B competing
Phase 3 or filed00 mid, 1 early
Pure plays0this indication only
Capital rank155/299crowding rank 168

Advanced Solid Tumors With FGFR1 Amplification is uncontested. Immunocore Holdings (IMCR) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Brenetafusp in phase 1.

There is no public comparable to price it against. IMCR spreads its $1.9B market cap across 2 indications, so $967M of it is allocated here.

Nothing here has reached Phase 3: 0 programmes in mid stage and 1 in early stage, so the field is still several years from a first approval.

$967M of allocated capital sits in Advanced Solid Tumors With FGFR1 Amplification, ranking it 155th of 299 indications by the money committed to it.

Companies developing drugs for Advanced Solid Tumors With FGFR1 Amplification 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
IMCRImmunocore HoldingsBrenetafuspPhase 11$1.9BNo2 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Advanced Solid Tumors With FGFR1 Amplification counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Advanced Solid Tumors With FGFR1 Amplification has one competitor and a median of $1.9B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Cutaneous Squamous Cell Carcinoma2 companies · $978M · median $2.6BConcentrated betEndometrial Cancer2 companies · $921M · median $2.1BConcentrated betCervical Cancer1 company · $848M · median $2.5BUncontestedDiffuse Large B-Cell Lymphoma3 companies · $834M · median $351MOrphan cornerCancer Pain1 company · $798M · median $4.0BUncontestedAdvanced EGFR Mutant Non-Small Cell Lung Cancer1 company · $794M · median $794MUncontestedGlioma1 company · $792M · median $2.4BUncontestedSmall Cell Lung Cancer Extensive Stage1 company · $1.1B · median $16.1BUncontested

Advanced Solid Tumors With FGFR1 Amplification pipeline questions

Which biotech companies are developing drugs for Advanced Solid Tumors With FGFR1 Amplification?

Immunocore Holdings (IMCR, Brenetafusp, Phase 1). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Advanced Solid Tumors With FGFR1 Amplification.

How advanced is the Advanced Solid Tumors With FGFR1 Amplification pipeline?

Of the 1 clinical-stage programme in Advanced Solid Tumors With FGFR1 Amplification, 0 are in Phase 3 or filed, 0 are in mid-stage development and 1 is in early-stage development.

Is anyone else developing a drug for Advanced Solid Tumors With FGFR1 Amplification?

No. IMCR is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Advanced Solid Tumors With FGFR1 Amplification, which is why the indication is classified as uncontested.

When is the next Advanced Solid Tumors With FGFR1 Amplification catalyst?

The next dated catalyst in Advanced Solid Tumors With FGFR1 Amplification is IMCR on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map